Patient characteristics
Sucessfully biopsied patients, N = 948 (%) | Matched treatment population, N = 199 (%) | |
---|---|---|
Age at inclusion | ||
N | 948 | 199 |
Median | 57 | 57 |
Range | 19–86 | 28–86 |
Sex | ||
Male | 485 (51%) | 85 (43%) |
Female | 463 (49%) | 114 (57%) |
ECOG performance status | ||
0 | 348 (46%) | 88 (50%) |
1 | 396 (52%) | 86 (49%) |
2 | 13 (2%) | 3 (2%) |
Missing | 191 | 22 |
Tumor type | ||
Head and neck | 111 (12%) | 15 (8%) |
Digestive | 197 (21%) | 46 (23%) |
Lung | 170 (18%) | 32 (16%) |
Bone | 11 (1%) | 0 (0%) |
Melanoma | 12 (1%) | 3 (2%) |
Mesothelioma and soft tissue | 26 (3%) | 4 (2%) |
Breast | 135 (14%) | 38 (19%) |
Gynecological, female | 83 (9%) | 24 (12%) |
Urological | 158 (16%) | 29 (15%) |
Central nervous system | 1 (0%) | 0 (0%) |
Thyroid and other endocrine glands | 8 (1%) | 2 (1%) |
Ill-defined primary tumor | 36 (4%) | 6 (3%) |
Metastasis at inclusion | ||
No (locally advanced) | 60 (6%) | 7 (4%) |
Yes | 887 (94%) | 192 (96%) |
Missing | 1 | 0 |
Number of metastatic sites | ||
Median | 2 | 2 |
Range | 0–9 | 0–9 |
Missing | 1 | 0 |
Number of previous therapies for advanced disease | ||
Median | 4 | 4 |
Range | 0–15 | 1–14 |
Missing | 19 | 0 |
RMH prognostic score | ||
N | 907 | 194 |
Median | 1 | 1 |
Range | 0–3 | 0–3 |
Missing | 41 | 5 |